NCT05491759View on ClinicalTrials.gov

A Study to Determine Optimal Absorption of Single Dose Omega-3

PHASE4CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 4, 2022

Primary Completion Date

September 28, 2022

Study Completion Date

September 28, 2022

Conditions
Optimal Gastrointestinal Absorption of Omega-3
Interventions
DRUG

Product 1 - AquaCelle Fish Oil Triglyceride

1 dose of 2 capsules equivalent to 1.6g Fish Oil Triglyceride (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)) and 0.4g AquaCelle.

DRUG

Product 2 - AquaCelle Fish Oil Ethyl Ester

1 dose of 2 capsules equivalent to 1.6g Fish Oil Ethyl Ester (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)) and 0.28g AquaCelle

DRUG

Product 3 - Standard Fish Oil Triglyceride

1 dose of 2 capsules equivalent to 1.6g Fish Oil Triglyceride (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)).

Trial Locations (1)

4006

RDC Global Pty Ltd, Brisbane

All Listed Sponsors
lead

RDC Clinical Pty Ltd

INDUSTRY